The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Subscribe To Our Newsletter & Stay Updated
